Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer

NCT02716311 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Afatinib
DRUG: Cetuximab

Sponsor

Intergroupe Francophone de Cancerologie Thoracique